GH Says GH001 Meets Primary Endpoint in Phase 2a Post-Partum Depression Trial

GH (NASDAQ: GH) on Friday, June 5, 2026, announced that its investigational drug GH001 met the primary endpoint in a Phase 2a clinical trial for post-partum depression (PPD). The company did not immediately release detailed efficacy or safety data. The positive readout marks a critical step toward later-stage development for the novel PPD therapy. GH plans to discuss a registrational path with regulators based on the findings. Shares of the diagnostics and therapeutics company have yet to react in early trading.